These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 11292011)

  • 1. Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers.
    Riba J; Rodríguez-Fornells A; Urbano G; Morte A; Antonijoan R; Montero M; Callaway JC; Barbanoj MJ
    Psychopharmacology (Berl); 2001 Feb; 154(1):85-95. PubMed ID: 11292011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers.
    Riba J; Anderer P; Morte A; Urbano G; Jané F; Saletu B; Barbanoj MJ
    Br J Clin Pharmacol; 2002 Jun; 53(6):613-28. PubMed ID: 12047486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of ayahuasca administered in two repeated doses.
    Dos Santos RG; Grasa E; Valle M; Ballester MR; Bouso JC; Nomdedéu JF; Homs R; Barbanoj MJ; Riba J
    Psychopharmacology (Berl); 2012 Feb; 219(4):1039-53. PubMed ID: 21842159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine.
    Dos Santos RG; Valle M; Bouso JC; Nomdedéu JF; Rodríguez-Espinosa J; McIlhenny EH; Barker SA; Barbanoj MJ; Riba J
    J Clin Psychopharmacol; 2011 Dec; 31(6):717-26. PubMed ID: 22005052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics.
    Riba J; Valle M; Urbano G; Yritia M; Morte A; Barbanoj MJ
    J Pharmacol Exp Ther; 2003 Jul; 306(1):73-83. PubMed ID: 12660312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: a functional neuroimaging study using low-resolution electromagnetic tomography.
    Riba J; Anderer P; Jané F; Saletu B; Barbanoj MJ
    Neuropsychobiology; 2004; 50(1):89-101. PubMed ID: 15179026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daytime Ayahuasca administration modulates REM and slow-wave sleep in healthy volunteers.
    Barbanoj MJ; Riba J; Clos S; Giménez S; Grasa E; Romero S
    Psychopharmacology (Berl); 2008 Feb; 196(2):315-26. PubMed ID: 18030450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness.
    Hamill J; Hallak J; Dursun SM; Baker G
    Curr Neuropharmacol; 2019; 17(2):108-128. PubMed ID: 29366418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychedelic Therapy: A Primer for Primary Care Clinicians-N,N-Dimethyltryptamine and Ayahuasca.
    Shinozuka K; Tabaac BJ; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS
    Am J Ther; 2024 Mar-Apr 01; 31(2):e112-e120. PubMed ID: 38518268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant.
    Riba J; Romero S; Grasa E; Mena E; Carrió I; Barbanoj MJ
    Psychopharmacology (Berl); 2006 May; 186(1):93-8. PubMed ID: 16575552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT).
    Cameron LP; Olson DE
    ACS Chem Neurosci; 2018 Oct; 9(10):2344-2357. PubMed ID: 30036036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans.
    Valle M; Maqueda AE; Rabella M; Rodríguez-Pujadas A; Antonijoan RM; Romero S; Alonso JF; Mañanas MÀ; Barker S; Friedlander P; Feilding A; Riba J
    Eur Neuropsychopharmacol; 2016 Jul; 26(7):1161-75. PubMed ID: 27039035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale.
    Strassman RJ; Qualls CR; Uhlenhuth EH; Kellner R
    Arch Gen Psychiatry; 1994 Feb; 51(2):98-108. PubMed ID: 8297217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dimethyltryptamine: Endogenous Role and Therapeutic Potential.
    Rodrigues AV; Almeida FJ; Vieira-Coelho MA
    J Psychoactive Drugs; 2019; 51(4):299-310. PubMed ID: 31018803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulatory effects of ayahuasca on personality structure in a traditional framework.
    Netzband N; Ruffell S; Linton S; Tsang WF; Wolff T
    Psychopharmacology (Berl); 2020 Oct; 237(10):3161-3171. PubMed ID: 32700023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health status of ayahuasca users.
    Barbosa PC; Mizumoto S; Bogenschutz MP; Strassman RJ
    Drug Test Anal; 2012; 4(7-8):601-9. PubMed ID: 22761152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively.
    Riba J; Rodríguez-Fornells A; Barbanoj MJ
    Psychopharmacology (Berl); 2002 Dec; 165(1):18-28. PubMed ID: 12474114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca.
    Riba J; McIlhenny EH; Valle M; Bouso JC; Barker SA
    Drug Test Anal; 2012; 4(7-8):610-6. PubMed ID: 22514127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca.
    McKenna DJ; Towers GH; Abbott F
    J Ethnopharmacol; 1984 Apr; 10(2):195-223. PubMed ID: 6587171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered State of Consciousness and Mental Imagery as a Function of N, N-dimethyltryptamine Concentration in Ritualistic Ayahuasca Users.
    Ramaekers JG; Mallaroni P; Kloft L; Reckweg JT; Toennes SW; van Oorsouw K; Mason NL
    J Cogn Neurosci; 2023 Sep; 35(9):1382-1393. PubMed ID: 37159257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.